Prevents deep vein thrombosis (DVT). ANDA 208615, held by Scinopharm Taiwan. Fondaparinux Sodium.
As of Nov 16, 2026, ANDA 208615 (Fondaparinux Sodium), held by Scinopharm Taiwan, was first approved by FDA on Nov 14, 2018, with 1 approved supplement and 0 published complete response letters.
Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. ( 1.2, 1.3 ) 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 14, 2018 | Original application | Approved | None posted |
| Fondaparinux Sodium2.5MG/0.5ML (2.5MG/0.5ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium5MG/0.4ML (5MG/0.4ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium7.5MG/0.6ML (7.5MG/0.6ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium10MG/0.8ML (10MG/0.8ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Sep 12, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 14, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters